Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $86,011 | $41,278 |
| General and administrative | 39,121 | 15,916 |
| Total operating expenses | 125,132 | 57,194 |
| Loss from operations | (125,132) | (57,194) |
| Other income (expense): | ||
| Interest income | 6,355 | 6,906 |
| Interest expense | (1,823) | (1,792) |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's G&A?
- Vera Therapeutics (VERA) reported G&A of $39.12M in Q1 2026.
- How has Vera Therapeutics's G&A changed year-over-year?
- Vera Therapeutics's G&A increased by 145.8% year-over-year, from $15.92M to $39.12M.
- What is the long-term trend for Vera Therapeutics's G&A?
- Over 4 years (2021 to 2025), Vera Therapeutics's G&A has grown at a 70.3% compound annual growth rate (CAGR), from $11.92M to $100.22M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Vera Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude